Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.

Drullinsky P, Sugarman SM, Fornier MN, D'Andrea G, Gilewski T, Lake D, Traina T, Wasserheit-Lieblich C, Sklarin N, Atieh-Graham D, Mills N, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C.

Clin Breast Cancer. 2010 Dec 1;10(6):440-4. doi: 10.3816/CBC.2010.n.057.

PMID:
21147686
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.

Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Lichtenegger W, Elling D.

Crit Rev Oncol Hematol. 2006 May;58(2):166-75. Epub 2006 Jan 18.

PMID:
16387512
[PubMed - indexed for MEDLINE]
3.

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.

Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Elling D.

Br J Cancer. 2006 May 8;94(9):1237-44.

PMID:
16622463
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

Di Leo A, Crown J, Nogaret JM, Duffy K, Bartholomeus S, Dolci S, Rowan S, O'Higgins N, Paesmans M, Larsimont D, Riva A, Piccart MJ.

Ann Oncol. 2000 Feb;11(2):169-75.

PMID:
10761751
[PubMed - indexed for MEDLINE]
Free Article
5.

Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.

Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group.

J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83.

PMID:
15265969
[PubMed - indexed for MEDLINE]
Free Article
6.

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF.

Ann Oncol. 2003 Feb;14(2):227-32.

PMID:
12562649
[PubMed - indexed for MEDLINE]
Free Article
7.

Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.

Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E 3rd, Henderson IC.

J Natl Cancer Inst. 1993 May 19;85(10):812-7.

PMID:
8487326
[PubMed - indexed for MEDLINE]
8.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

Ann Oncol. 2003 Jun;14(6):833-42. Review.

PMID:
12796019
[PubMed - indexed for MEDLINE]
Free Article
9.

Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer.

Fornier MN, Seidman AD, Lake D, D'Andrea G, Bromberg J, Robson M, Van Poznak C, Panageas KS, Atienza M, Norton L, Hudis C.

Clin Cancer Res. 2007 Jan 1;13(1):223-7.

PMID:
17200358
[PubMed - indexed for MEDLINE]
Free Article
10.

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.

Senn HJ, Maibach R, Castiglione M, Jungi WF, Cavalli F, Leyvraz S, Obrecht JP, Schildknecht O, Siegenthaler P.

J Clin Oncol. 1997 Jul;15(7):2502-9.

PMID:
9215818
[PubMed - indexed for MEDLINE]
11.

Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.

Mattioli R, Gridelli C, Castellanos J, Duque A, Falcone A, Mansutti M, Bacon P, Lawrinson S, Skacel T, Casas A.

Clin Transl Oncol. 2009 Dec;11(12):842-8.

PMID:
20045791
[PubMed - indexed for MEDLINE]
12.

Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group.

J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. doi: 10.1093/jnci/djm287. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Nov 19;100(22):1655.

PMID:
18182617
[PubMed - indexed for MEDLINE]
Free Article
13.

Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.

Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer.

Breast Cancer. 2010 Jul;17(3):190-8. doi: 10.1007/s12282-009-0132-x. Epub 2009 Jul 3.

PMID:
19575284
[PubMed - indexed for MEDLINE]
14.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.

Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators.

Ann Oncol. 2011 Sep;22(9):1988-98. doi: 10.1093/annonc/mdq709. Epub 2011 Mar 8.

PMID:
21385882
[PubMed - indexed for MEDLINE]
Free Article
15.

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.

Ejlertsen B, Mouridsen HT, Jensen MB.

Acta Oncol. 2008;47(4):662-71. doi: 10.1080/02841860801989761.

PMID:
18465334
[PubMed - indexed for MEDLINE]
17.

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G.

J Clin Oncol. 1996 Apr;14(4):1136-45.

PMID:
8648368
[PubMed - indexed for MEDLINE]
18.

Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.

Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK.

Cancer. 2000 Dec 15;89(12):2521-6.

PMID:
11135211
[PubMed - indexed for MEDLINE]
19.
20.

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.

Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators.

Ann Oncol. 2011 Sep;22(9):1999-2006. doi: 10.1093/annonc/mdq713. Epub 2011 Mar 7.

PMID:
21382868
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk